20-F: NuCana plc Releases 2024 Financial Results in Form 20-F Filing

NuCana plc reports its 2024 financial results, highlighting ongoing clinical trials and future plans in its annual Form 20-F filing.

Summary

• NuCana plc has released its 20-F filing, detailing the company's financial performance for the year ended December 31, 2024.
• The company incurred net losses of $30.7 million in 2020, $40.5 million in 2021, $32.0 million in 2022, $27.6 million in 2023, and $19.0 million in 2024.
• As of December 31, 2024, NuCana had an accumulated deficit of $224.3 million.
• The company's product candidate, NUC-7738, is currently in Phase 2 of a Phase 1/2 clinical trial.
• NUC-3373 is being evaluated in a Phase 1b/2 modular clinical trial.
• NuCana is dependent on the success of its product candidates, NUC-7738 and NUC-3373.
• The company plans to seek regulatory approval to commercialize NUC-7738 and NUC-3373 in the United States and the European Union.
• NuCana believes its cash and cash equivalents on hand will not be sufficient to fund its anticipated operations for at least the next twelve months.
• The company plans to commence an equity financing process to raise additional capital.
• As of December 31, 2024, NuCana had cumulative carry forward tax losses of $104.2 million.
• The company is subject to the U.K. Bribery Act, the U.S. Foreign Corrupt Practices Act, and other anti-corruption laws.
• NuCana relies on third parties to conduct clinical trials and manufacture its product candidates.
• The company faces substantial competition in the biopharmaceutical industry.
• NuCana's future success depends on its ability to obtain and maintain intellectual property protection.
• The price of NuCana's ADSs may be volatile and fluctuate due to factors beyond its control.
• The company will continue to incur increased costs as a result of operating as a public company in the United States.
• Certain existing shareholders, members of the board of directors, and senior management maintain the ability to exercise significant control over NuCana.
• Future sales of a substantial number of NuCana's ADSs or ordinary shares could adversely affect the price of its ADSs.
• Holders of NuCana's ADSs may be subject to limitations on the transfer of their ADSs.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there's a decrease in net losses and R&D expenses, the company's financial position raises concerns about its ability to continue as a going concern without raising additional capital. The reliance on future success of clinical trials and regulatory approvals adds uncertainty.

Positives

• NuCana's net losses have decreased from $27.6 million in 2023 to $19.0 million in 2024.
• The company's research and development expenses decreased from $25.062 million in 2023 to $18.017 million in 2024.
• The company is seeking regulatory guidance from the FDA on its registrational strategy for NUC-7738 in melanoma in 2025.
• The company is planning to initiate an expansion of the NuTide:701 trial of NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma in 2025.
• The company is planning to announce data from the NuTide:303 trial of NUC-3373 in combination with pembrolizumab in patients with solid tumors in 2025.

Negatives

• NuCana has incurred significant operating losses since its inception and expects to continue to do so for the foreseeable future.
• The company believes its cash and cash equivalents on hand will not be sufficient to fund its anticipated operations for at least the next twelve months.
• NuCana plans to commence an equity financing process to raise additional capital.
• The company is dependent on the success of its product candidates, NUC-7738 and NUC-3373.
• The price of NuCana's ADSs may be volatile and fluctuate due to factors beyond its control.

Risks

• NuCana's ability to continue as a going concern is subject to substantial doubt.
• The company's dependence on the success of NUC-7738 and NUC-3373 carries significant risk.
• Clinical trials may be delayed or prevented, impacting the development and approval of product candidates.
• The company relies on third parties for clinical trials and manufacturing, which could lead to delays or insufficient quantities of product candidates.
• NuCana faces substantial competition in the biopharmaceutical industry.
• The company's intellectual property rights may not be adequately protected.
• Exchange rate fluctuations may adversely affect NuCana's results of operations and financial condition.
• The price of NuCana's ADSs may be volatile and fluctuate due to factors beyond its control.
• The company may be unable to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future tax payments or benefit from favorable United Kingdom tax legislation.

Future Outlook

NuCana plans to continue the clinical development of NUC-7738 and NUC-3373, seek regulatory approval in the United States and the European Union, and explore additional indications for its product candidates. The company anticipates needing to raise additional capital to fund its operations.

Industry Context

NuCana operates in the highly competitive biopharmaceutical industry, facing competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. The company is focused on developing ProTides, which are designed to improve the efficacy and safety of existing chemotherapy agents.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document does mention that the company is competing with major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide.
• The document also mentions that the company is focused on developing ProTides, which are designed to improve the efficacy and safety of existing chemotherapy agents.
• The document does not provide any specific information about the financial performance of these companies, or the success rates of their clinical trials.
• Therefore, it is not possible to make a detailed comparison to industry standards.

Management Changes

Stakeholder Impact

• Shareholders face potential dilution from future equity financings.
• Employees face uncertainty due to the company's financial situation.
• Patients may benefit from the development of new cancer treatments.
• Suppliers and creditors face potential risks due to the company's financial situation.

Next Steps

• Initiate an expansion of the NuTide:701 trial of NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma in 2025.
• Announce data from this NuTide:701 expansion study.
• Obtain regulatory guidance from the FDA on its registrational strategy for NUC-7738 in melanoma in 2025.
• Announce data from the NuTide:303 trial of NUC-3373 in combination with pembrolizumab in patients with solid tumors in 2025.
• Hold a general meeting on April 7, 2025 to approve the sub-division and related redesignation of our ordinary shares.

Key Dates

Keywords

NuCana, NUC-7738, NUC-3373, clinical trials, financial results, biopharmaceutical, oncology, ProTide, regulatory approval, share options